Jubilant Pharmova Expands Spokane Facility with New Injectable Line

Jubilant Pharmova Limited has announced the successful launch of its third sterile injectable line at the Spokane, Washington, facility, significantly enhancing its production capabilities. This expansion, powered by a substantial investment of US$132 million, increases the facility’s capacity by 50% and is designed to support complex injectable programs.

The new line, operated by Jubilant’s wholly owned subsidiary, Jubilant HollisterStier (JHS), has already begun production with its inaugural batch. This marks a pivotal moment for the company, as it initiates revenue generation from this latest expansion. The investment is part of a comprehensive growth strategy aimed at doubling sterile manufacturing capacity in the United States.

Enhancing Production with Advanced Technology

The newly launched line incorporates cutting-edge isolator technology, which improves sterility assurance and operational precision. This advancement aligns with global regulatory standards, positioning Jubilant HollisterStier as a leader in the sterile injectable market. The addition of this line not only boosts production capabilities but also strengthens the company’s commitment to quality and compliance.

Chris Preti, CEO of CDMO Sterile Injectables at Jubilant HollisterStier, emphasized the significance of this milestone. He stated, “Launching our Third Line is more than a milestone for us—it’s a defining moment in Jubilant HollisterStier’s journey. With Third Line now operational and Fourth Line on the horizon, we are not just doubling our capacity, we’re building a future that will create hundreds of new jobs, strengthen the US pharmaceutical supply chain, and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world.”

Jubilant HollisterStier serves a diverse client base, including five of the top 20 global pharmaceutical companies. The company boasts a customer retention rate of 92% and is committed to maintaining compliance with various regulatory authorities, such as the US FDA, EMA, PMDA in Japan, Health Canada, and ANVISA in Brazil, among others. This compliance is crucial as the company operates across more than 140 countries.

As the pharmaceutical industry continues to evolve, Jubilant Pharmova’s strategic expansions reflect its dedication to enhancing the supply chain and meeting the growing demand for sterile injectables. The launch of this third line is a clear indication of the company’s robust growth trajectory and its commitment to improving health outcomes globally.